

WINNER PROFILE



➔ **Meet: Sourav Sinha, Founder and CEO of Oncolinx Pharmaceuticals Boston, Massachusetts**

➔ **The Challenge: Breast Cancer Startup**

The National Institutes of Health (NIH) National Cancer Institute (NCI) teamed with the Avon Foundation to inspire teams of entrepreneurs to create business plans and start new companies to commercialize technologies that can advance breast cancer research.

➔ **The Prize:**

The opportunity to interface with potential investors and start a business

💡 **The Solution:**

The Oncolinx team developed a business strategy to develop and market novel toxins that can be used in therapies that target drug-resistant tumors for less money and with fewer side effects.

☎ **For More About the Winner:**

Sourav Sinha
Phone: 848-391-9367
Email: sourav@oncolinx.com

SUCCESS: IN HIS OWN WORDS

How has participating in this challenge helped you advance your solution?

The challenge gave us access to some great early-stage research that we were able to advance to address unmet medical needs. With plans to open first-in-human trials in the next 12 to 18 months, we are excited for the opportunity to treat patients who currently have very limited treatment options.

What is the impact of your solution for government, your community, and society?

Oncolinx is rooted in the endeavor to make a meaningful impact on human health, the overall mission of the NCI and NIH. The NIH drives some of the most innovative research in the world. However, most of the research and inventions don't reach patients. Working with the NIH and NCI, Oncolinx continues the development of this early stage research to move these novel therapies into patients. Many of the orphan cancer indications that we target are for patients who have very limited treatment options.

